Literature DB >> 32357967

Trying for a BRAF Slam Dunk.

Antoni Ribas1, Roger S Lo1.   

Abstract

The first basket clinical trial testing the BRAF inhibitor vemurafenib resulted in evidence of activity in 13 unique cancer types with BRAF V600 mutations, but the response rates were variable. Therefore, different cancer histologies with the same driver oncogene display different degrees of oncogenic pathway addiction.See related article by Subbiah et al., p. 657. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID： 32357967      PMCID： PMC7363198          DOI： 10.1158/2159-8290.CD-20-0231

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  15 in total

1.  Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.

Authors:  Willy Hugo; Hubing Shi; Lu Sun; Marco Piva; Chunying Song; Xiangju Kong; Gatien Moriceau; Aayoung Hong; Kimberly B Dahlman; Douglas B Johnson; Jeffrey A Sosman; Antoni Ribas; Roger S Lo
Journal:  Cell       Date:  2015-09-10       Impact factor: 41.582

2.  'Basket studies' will hold intricate data for cancer drug approvals.

Authors:  Cassandra Willyard
Journal:  Nat Med       Date:  2013-06       Impact factor: 53.440

3.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

4.  Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Authors:  Alexander Drilon; Theodore W Laetsch; Shivaani Kummar; Steven G DuBois; Ulrik N Lassen; George D Demetri; Michael Nathenson; Robert C Doebele; Anna F Farago; Alberto S Pappo; Brian Turpin; Afshin Dowlati; Marcia S Brose; Leo Mascarenhas; Noah Federman; Jordan Berlin; Wafik S El-Deiry; Christina Baik; John Deeken; Valentina Boni; Ramamoorthy Nagasubramanian; Matthew Taylor; Erin R Rudzinski; Funda Meric-Bernstam; Davendra P S Sohal; Patrick C Ma; Luis E Raez; Jaclyn F Hechtman; Ryma Benayed; Marc Ladanyi; Brian B Tuch; Kevin Ebata; Scott Cruickshank; Nora C Ku; Michael C Cox; Douglas S Hawkins; David S Hong; David M Hyman
Journal:  N Engl J Med       Date:  2018-02-22       Impact factor: 91.245

5.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

6.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Authors:  Ramin Nazarian; Hubing Shi; Qi Wang; Xiangju Kong; Richard C Koya; Hane Lee; Zugen Chen; Mi-Kyung Lee; Narsis Attar; Hooman Sazegar; Thinle Chodon; Stanley F Nelson; Grant McArthur; Jeffrey A Sosman; Antoni Ribas; Roger S Lo
Journal:  Nature       Date:  2010-11-24       Impact factor: 49.962

7.  FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.

Authors:  Leigh Marcus; Steven J Lemery; Patricia Keegan; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2019-02-20       Impact factor: 12.531

8.  Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.

Authors:  Gatien Moriceau; Willy Hugo; Aayoung Hong; Hubing Shi; Xiangju Kong; Clarissa C Yu; Richard C Koya; Ahmed A Samatar; Negar Khanlou; Jonathan Braun; Kathleen Ruchalski; Heike Seifert; James Larkin; Kimberly B Dahlman; Douglas B Johnson; Alain Algazi; Jeffrey A Sosman; Antoni Ribas; Roger S Lo
Journal:  Cancer Cell       Date:  2015-01-15       Impact factor: 31.743

9.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Authors:  David M Hyman; Igor Puzanov; Vivek Subbiah; Jason E Faris; Ian Chau; Jean-Yves Blay; Jürgen Wolf; Noopur S Raje; Eli L Diamond; Antoine Hollebecque; Radj Gervais; Maria Elena Elez-Fernandez; Antoine Italiano; Ralf-Dieter Hofheinz; Manuel Hidalgo; Emily Chan; Martin Schuler; Susan Frances Lasserre; Martina Makrutzki; Florin Sirzen; Maria Luisa Veronese; Josep Tabernero; José Baselga
Journal:  N Engl J Med       Date:  2015-08-20       Impact factor: 91.245

10.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Authors:  Hubing Shi; Willy Hugo; Xiangju Kong; Aayoung Hong; Richard C Koya; Gatien Moriceau; Thinle Chodon; Rongqing Guo; Douglas B Johnson; Kimberly B Dahlman; Mark C Kelley; Richard F Kefford; Bartosz Chmielowski; John A Glaspy; Jeffrey A Sosman; Nicolas van Baren; Georgina V Long; Antoni Ribas; Roger S Lo
Journal:  Cancer Discov       Date:  2013-11-21       Impact factor: 39.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.